[Characteristics and failure risk factors of sequential high-flow nasal cannula oxygen therapy after weaning from invasive ventilation in patients of surgical intensive care unit].


Journal

Zhonghua wei zhong bing ji jiu yi xue
ISSN: 2095-4352
Titre abrégé: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
Pays: China
ID NLM: 101604552

Informations de publication

Date de publication:
Jun 2019
Historique:
entrez: 19 7 2019
pubmed: 19 7 2019
medline: 19 9 2019
Statut: ppublish

Résumé

To investigate the characteristics and failure risk factors of sequential high-flow nasal cannula oxygen therapy (HFNC) after weaning from invasive ventilation. The patients who received sequential HFNC after weaning from invasive ventilation admitted to surgical intensive care unit (ICU) of Peking University People's Hospital from June 1st 2016 to May 31st 2018 were retrospectively analyzed. Clinical variables, respiratory therapy parameters, respiratory variables, cardiac variables and outcomes were reviewed and analyzed. Treatment characteristics of HFNC after weaning was analyzed. Patients were divided into HFNC success group and HFNC failure group according to the failure of HFNC, and the differences between the two groups were compared. The independent risk factors of HFNC treatment failure were analyzed by Logistic regression analysis. The value of predictive treatment failure of risk factors and regression models were analyzed by receiver operating characteristic (ROC) curve. A total of 99 patients were included, 61 men, and the median age was 67.0 (57.0, 76.0) years old. The medianinitial HFNC flow was 50 (50, 60) L/min, and inspired oxygen concentration (FiO HFNC is one of the commonly used oxygen therapy methods in the ICU, but not all patients who are treated as a sequential therapy after invasive mechanical ventilation weaning can benefit from it. SOFA score, BNP before HFNC treatment and HR after 30 minutes HFNC treatment were independent risk factors of HFNC failure. Each independent risk factor and regression model can predict the success of HFNC treatment.

Identifiants

pubmed: 31315724
doi: 10.3760/cma.j.issn.2095-4352.2019.06.006
doi:

Types de publication

Journal Article

Langues

chi

Sous-ensembles de citation

IM

Pagination

689-693

Auteurs

Huiying Zhao (H)

Department of Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Jian Luo (J)

Ji'an County People's Hospital, Ji'an 343100, Jiangxi, China. Corresponding author: An Youzhong, Email: bjicu@163.com.

Jie Lyu (J)

Department of Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Huixia Wang (H)

Department of Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Huijuan Ji (H)

Department of Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Youzhong An (Y)

Department of Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH